Market reactionShares fell 17% on Nov 2.
Helus Pharma is a clinical-stage company developing HLP003, an oral psilocin-based drug taken as an add-on treatment for major depressive disorder; it is not approved.
Helus's case rests on HLP003, a Breakthrough-designated deuterated psilocin analog being developed as an add-on for major depressive disorder. APPROACH completed enrollment, with topline expected in Q4 2026; EMBRACE continues enrolling toward a targeted 2028 NDA. Phase 2 durability supports the opportunity, while pivotal benefit, long-term safety and funding remain central questions. The completed June $50 million offering supports development. HLP004 adds a second opportunity in generalized anxiety disorder, now pursuing monotherapy with a Phase 2 study expected to start in Q1 2027.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: APPROACH shows a clear benefit over placebo
Does adjunctive HLP003 deliver a clear MADRS benefit over placebo with acceptable safety and sustained improvement?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
HLP003 pivotal readout remains expected in Q4 2026 as leadership transition continues
Dual-BTD psilocybin analog in two Phase 3 pivotals for MDD, but a $42M/quarter burn means survival to NDA hinges on APPROACH data and follow-on financing
Dual BTD psilocybin analog racing two Phase 3 trials toward 2028 NDA, contingent on APPROACH data validating the MDD adjunctive case
CYB003's dual Phase 3 PARADIGM program tests whether a deuterated psilocybin analog can deliver registrational MDD efficacy before the psychedelic field consolidates around a first mover
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Psychiatric disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.